bluebird bio, Inc. (BLUE) is a company focusing on severe genetic diseases and engaged in the development of clinical portfolios for sickle cell anemia, thalassemia, and cerebral adrenoleukodystrophy. The company has one of the largest and deepest ex-vivo gene therapy data set globally.
The price of BLUE stock during regular early trading on March 7, 2022, was last checked to be $4.42 with a dive of 11.50%.
BLUE: Key Financials
On March 4, 2022, BLUE announced its consolidated unaudited financial outcomes for the fourth quarter of 2021 ended December 31, 2021. Some of the central features are as follows
Revenue
Total revenue in Q4 2021 was $1.6 million versus no revenue in the same period of 2020. The company recorded a considerable gain in its total revenue over the year. Also, it missed the analysts’ revenue estimates by $4.11 million.
EPS
Net loss basic and diluted per share in the fourth quarter of 2021 was $155 million or $2.14 against $199.8 million or $3.01 per share for the same period in 2020. The company observed a significant gain in its EPS over the year and also missed the EPS estimates by -$0.38.
BLUE: Events and Happenings
On January 18, 2022, BLUE reported the extension of the biologics licensing applications review period by the FDA for the company’s lentiviral vector gene therapies. The revised dates for beti-cel and eli-cel gene therapies are August 19, 2022, and September 16, 2022, respectively.
On January 11, 2022, BLUE announced its executive management’s participation at the 40th Annual J.P. Morgan Healthcare Conference held on January 10-13, 2022. On December 20, 2021, BLUE was updated on the placement of the partial clinical hold by the FDA on its lovo-cel gene therapy for sickle cell disease. The temporary hold is the consequence of an investigation by the company into a patient with persistent, non-transfusion-dependent anemia 18 months post-treatment.
Conclusion
BLUE stock downplayed by 79% in 2021 as the pandemic was at its peak and it impacted the research pace of the company. The current stock decline in the early trading is an outcome of missing the analysts’ estimates of revenue and earnings per share.
